[
  {
    "chunk_id": "rr6007_chunk_0",
    "document_id": "rr6007",
    "text": "[Section: C\nR\nR\nR\nR]\nAbbreviations: R = recommended; C = contraindicated; UI = use if indicated; IPV = inactivated poliovirus vaccine.\n\t *\tPersons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental \nprofessionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care institutions). \nSource: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/vacctoolkit/\ndefinition.html.\n\t †\tSevere immunosuppression can be caused by congenital immunodeficiency, leukemia, lymphoma, generalized malignancy or therapy with alkylating agents,",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 0,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_1",
    "document_id": "rr6007",
    "text": "antimetabolites, ionizing radiation, or large amounts of corticosteroids.\n\t §\tWomen who are or will be pregnant  during the influenza season.\n\t ¶\tContraindicated in HIV-infected persons who have evidence of severe immunosuppression.\n\t**\tRecommendation is based on the person’s underlying condition rather than occupation.\n\t††\tVaccination is recommended for unvaccinated HCP who have close contact with patients who may be excreting wild polioviruses. HCP who have had a primary \nseries of oral poliovirus vaccine (OPV) or IPV who are directly involved with the provision of care to patients who may be excreting poliovirus may receive another",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 1,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_2",
    "document_id": "rr6007",
    "text": "dose of either IPV or OPV. Any suspected case of poliomyelitis should be investigated immediately. If evidence suggests transmission of poliovirus, control measures \nto contain further transmission should be instituted immediately.\n\t§§\tCapsular polysaccharide parenteral vaccine.\n\t¶¶\tVaricella vaccine may be considered for HIV-infected adults without evidence of immunity and with CD4 T-lymphocyte count ≥200 cells/Ul.\nTABLE 4. Recommended postexposure prophylaxis for percutaneous or permucosal \nexposure to hepatitis B virus — Advisory Committee on Immunization Practices, United States\nVaccination and antibody \nresponse status of exposed \nperson\nTreatment\nSource HBsAg-positive\nSource HBsAg-negative\nSource not tested or status unknown\nUnvaccinated\nHBIG x 1; initiate HB vaccine series",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 2,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_3",
    "document_id": "rr6007",
    "text": "Source not tested or status unknown\nUnvaccinated\nHBIG x 1; initiate HB vaccine series\nInitiate HB vaccine series\nInitiate HB vaccine series\nPreviously vaccinated\nKnown responder\nNo treatment\nNo treatment\nNo treatment\nKnown nonresponder\nAfter 3 doses\nHBIG x 1 and initiate revaccination\nNo treatment\nIf known high-risk source, treat as if source \nwere HBsAg-positive\nAfter 6 doses\nHBIG x 2 (separated by 1 month)\nNo treatment\nIf known high-risk source, treat as if source \nwere HBsAg-positive\nAntibody response unknown\nTest exposed person for anti-HBs\nIf adequate,* no treatment\nIf inadequate,* HBIG x 1 and vaccine booster\nNo treatment\nTest exposed person for anti-HBs\nIf adequate,* no treatment\nIf inadequate,* initiate revaccination",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 3,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_4",
    "document_id": "rr6007",
    "text": "Test exposed person for anti-HBs\nIf adequate,* no treatment\nIf inadequate,* initiate revaccination\nAbbreviations: HBsAg = Hepatitis B surface antigen; HBIG = hepatitis B immune globulin; anti-HBs = antibody to hepatitis B surface antigen; HB = hepatitis B.\nSource: Adapted from CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR 2006;55(No. RR-16).\n*\tA seroprotective (adequate) level of anti-HBs after completion of a vaccination series is defined as anti-HBs ≥10 mlU/mL; a response < 10 mlU/mL is inadequate and \nis not a reliable indicator of protection.\nRecommendations and Reports",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 4,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_5",
    "document_id": "rr6007",
    "text": "is not a reliable indicator of protection.\nRecommendations and Reports\nMMWR  /  November 25, 2011  /  Vol. 60  /  No. 7\t\n43\nTABLE 5. Advisory Committee on Immunization Practices work restrictions for health-care personnel* (HCP) exposed to or infected with certain \nvaccine-preventable diseases and conditions\nDisease/Condition \nWork restriction\nDuration\nHepatitis B\nHCP positive for HBsAg (e.g., acute or chronic \nhepatitis B infection):\nHCP who do not perform exposure-prone \ninvasive procedures \nNo restriction unless linked \nepidemiologically to transmission of \nhepatitis B virus infection\nStandard precautions always should be observed\nHCP who perform exposure-prone \ninvasive procedures\nThese HCP should not perform \nexposure-prone invasive procedures \nuntil they have sought counsel",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 5,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_6",
    "document_id": "rr6007",
    "text": "These HCP should not perform \nexposure-prone invasive procedures \nuntil they have sought counsel \nfrom an expert review panel, which \nshould review and recommend the \nprocedures the worker can perform, \ntaking into account the specific \nprocedure as well as the skill and \ntechnique of the worker \nPer recommendation of expert panel\nUpper respiratory infections\nHCP in contact with persons at high risk for \ncomplications of influenza†\nExclude from duty\nUntil afebrile ≥24 hours (without the use of fever-reducing medicines \nsuch as acetaminophen). Those with ongoing respiratory symptoms \nshould be considered for evaluation by occupational health to \ndetermine appropriateness of contact with patients. If returning to \ncare for patients in a protective environment (e.g., hematopoietic",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 6,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_7",
    "document_id": "rr6007",
    "text": "care for patients in a protective environment (e.g., hematopoietic \nstem cell transplant patients), consider for temporary reassignment \nor exclusion from work for 7 days from symptom onset or until the \nresolution of symptoms, whichever is longer. \nThose who develop acute respiratory symptoms without fever should \nbe considered for evaluation by occupational health to determine \nappropriateness of contact with patients and can be allowed to \nwork unless caring for patients in a protective environment; these \npersonnel should be considered for temporary reassignment \nor exclusion from work for 7 days from symptom onset or until \nthe resolution of all noncough symptoms, whichever is longer. If \nsymptoms such as cough and sneezing are still present, HCP should",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 7,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_8",
    "document_id": "rr6007",
    "text": "symptoms such as cough and sneezing are still present, HCP should \nwear a facemask during patient care activities. The importance of \nperforming frequent hand hygiene (especially before and after each \npatient contact) should be reinforced.\nMeasles\nActive\nExclude from duty\n4 days after rash appears\nPostexposure (HCP without presumptive \nevidence of measles immunity)\nExclude from duty\n5 days after first exposure through 21 days after last exposure and/or \n4 days after the rash appears\nMumps\nActive\nExclude from duty\n5 days after onset of parotitis\nPostexposure (HCP without presumptive \nevidence of mumps immunity)\nExclude from duty\n12 days after first exposure through 25 days after last exposure or 5 \ndays after onset of parotitis\nPertussis\nActive\nExclude from duty",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 8,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_9",
    "document_id": "rr6007",
    "text": "days after onset of parotitis\nPertussis\nActive\nExclude from duty\nBeginning of catarrhal stage through third week after onset of \nparoxysms or until 5 days after start of effective antimicrobial therapy\nPostexposure\nSymptomatic personnel\nExclude from duty\n5 days after start of effective antimicrobial therapy\nAsymptomatic personnel – HCP likely to expose a \npatient at risk for severe pertussis§\nNo restriction from duty; on \nantimicrobial prophylactic therapy\nAsymptomatic personnel – other HCP\nNo restriction from duty; can receive \npostexposure prophylaxis or be \nmonitored for 21 days after pertussis \nexposure and treated at the onset of \nsigns and symptoms of pertussis\nSee table footnotes on page 44\nRecommendations and Reports\n44\t\nMMWR  /  November 25, 2011  /  Vol. 60  /  No. 7",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 9,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_10",
    "document_id": "rr6007",
    "text": "Recommendations and Reports\n44\t\nMMWR  /  November 25, 2011  /  Vol. 60  /  No. 7\nTABLE 5. (Continued) Advisory Committee on Immunization Practices work restrictions for health-care personnel* (HCP) exposed to or infected \nwith certain vaccine-preventable diseases and conditions\nDisease/Condition \nWork restriction\nDuration\nRubella\nActive\nExclude from duty\n7 days after the rash appears\nPostexposure (personnel without evidence of \nrubella immunity)\nExclude from duty\n7 days after first exposure through 23 days after last exposure \nand/or 7 days after rash appears\nVaricella\nActive\nExclude from duty\nUntil all lesions dry and crust. If only lesions that do not crust \n(i.e., macules and papules), until no new lesions appear within a \n24-hour period\nPostexposure (HCP without evidence of varicella",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 10,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_11",
    "document_id": "rr6007",
    "text": "24-hour period\nPostexposure (HCP without evidence of varicella \nimmunity)\nExclude from duty unless receipt of \nthe second dose within 3-5 days after \nexposure\n8th day after 1st exposure through 21st day (28th day if varicella-\nzoster immune globulin administered) after the last exposure; if \nvaricella occurs, until all lesions dry and crust or, if only lesions that \ndo not crust (i.e., macules and papules), until no new lesions appear \nwithin a 24-hour period\nHerpes zoster\nLocalized in immunocompetent person\nCover lesions; restrict from care of \nhigh-risk patients¶\nUntil all lesions dry and crust\nDisseminated or localized in immunocompromised \nperson until disseminated infection is ruled out \nExclude from duty\nUntil all lesions dry and crust",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 11,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_12",
    "document_id": "rr6007",
    "text": "person until disseminated infection is ruled out \nExclude from duty\nUntil all lesions dry and crust\nPostexposure (HCP without evidence of varicella \nimmunity)\nDisseminated zoster or localized zoster with \nuncontained/uncovered lesions\nExclude from duty unless receipt of \nthe second dose of varicella vaccine \nwithin 3–5 days after exposure\n8th day after 1st exposure through 21st day (28th day if varicella-\nzoster immune globulin administered) after the last exposure; if \nvaricella occurs, until all lesions dry and crust or, if only lesions that \ndo not crust (i.e., macules and papules), until no new lesions appear \nwithin a 24-hour period\nLocalized zoster with contained/covered lesions\nFor HCP with at least 1dose of \nvaricella vaccine, no work restrictions.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 12,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_13",
    "document_id": "rr6007",
    "text": "For HCP with at least 1dose of \nvaricella vaccine, no work restrictions. \nFor HCP with no doses of varicella \nvaccine, restrict from patient contact\n8th day after 1st exposure through 21st day (28th day if varicella-\nzoster immune globulin administered) after the last exposure; if \nvaricella occurs, until all lesions dry and crust or, if only lesions that \ndo not crust (i.e., macules and papules), until no new lesions appear \nwithin a 24-hour period\nAbbreviation: HBsAg = hepatitis B surface antigen.\nSources: Adapted from CDC. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 13,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_14",
    "document_id": "rr6007",
    "text": "prone invasive procedures. MMWR 1991;40(No. RR-8); CDC. Guideline for isolation precautions in hospitals: recommendations of the Hospital Infection Control Practices \nAdvisory Committee (HICPAC) and the National Center for Infectious Diseases. Infect Control Hosp Epidemiol 1996;17:53–80; Williams WW. CDC guideline for infection \ncontrol in hospital personnel. Infect Control 1983;4(Suppl):326–49; CDC. Immunization of health-care workers: recommendations of the Advisory Committee on \nImmunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1997;46(No. RR-18).\n*\tPersons who provide health care to patients or work in institutions that provide patient care (e. g., physicians, nurses, emergency medical personnel, dental",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 14,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_15",
    "document_id": "rr6007",
    "text": "professionals and students, medical and nursing students, laboratory technicians, hospital volunteers, and administrative and support staff in health-care institutions). \nSource: U.S. Department of Health and Human Services. Definition of health-care personnel (HCP). Available at http://www.hhs.gov/ask/initiatives/vacctoolkit/\ndefinition.html.\n†\tIncludes children aged <5 years, adults aged ≥65 years, pregnant women, American Indians/Alaska Natives, persons aged <19 years who are receiving long-term \naspirin therapy, and persons with certain high-risk medical conditions (i.e., asthma, neurologic and neurodevelopmental conditions, chronic lung disease, heart",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 15,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_16",
    "document_id": "rr6007",
    "text": "disease, blood disorders, endocrine disorders, kidney disorders, liver disorders, metabolic disorders, weakened immune system due to disease or medication, and \nmorbid obesity). \n§\tIncludes hospitalized neonates and pregnant women.\n¶\tIncludes patients who are susceptible to varicella and at increased risk for complications of varicella (i.e., neonates, pregnant women, and immunocompromised \npersons of any age).\nRecommendations and Reports\nMMWR  /  November 25, 2011  /  Vol. 60  /  No. 7\t\n45\nAdvisory Committee on Immunization Practices\nMembership List, February 2011\nChair: Carol Baker, MD, Baylor College of Medicine, Houston, Texas.\nExecutive Secretary: Larry Pickering, MD, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 16,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_17",
    "document_id": "rr6007",
    "text": "Members: Lance Chilton, MD, University of New Mexico, Albuquerque, New Mexico; Paul Cieslak, MD, Oregon Public Health Division, Portland, Oregon; \nTamera Coyne-Beasley, MD, University of North Carolina, Chapel Hill, North Carolina; Jeffrey Duchin, MD, University of Washington, Seattle, Washington; \nKristen Ehresmann, MPH, Minnesota Department of Health, St Paul, Minnesota; Janet Englund, MD, University of Washington and Children’s Hospital \nand Regional Medical Center, Seattle, Washington; Renée Jenkins, MD, Howard University School of Medicine, District of Columbia; Franklyn Judson, \nMD, University of Colorado Health Sciences Center, Denver, Colorado; Wendy Keitel, MD, Baylor College of Medicine, Houston, Texas; Michael Marcy,",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 17,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_18",
    "document_id": "rr6007",
    "text": "MD, UCLA Center for Vaccine Research, Torrance, California; Cody Meissner, MD, Tufts Medical Center, Boston, Massachusetts; Sara Rosenbaum, JD, \nGeorgetown University, District of Columbia; Mark Sawyer, MD, University of California at San Diego, California; Jonathan Temte, MD, University of \nWisconsin School of Medicine and Public Health, Madison, Wisconsin.\nEx Officio Members: James E. Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Geoffrey S. Evans, MD, Health Resources and Services \nAdministration, Rockville, Maryland; Jesse Geibe, MD, Department of Defense, CDC, Atlanta, Georgia; Bruce Gellin, MD, National Vaccine Program \nOffice, District of Columba; Richard Gorman, MD, National Institutes of Health, Bethesda, Maryland; Linda Murphy, Centers for Medicare and Medicaid",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 18,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_19",
    "document_id": "rr6007",
    "text": "Services, Baltimore, Maryland; Norman Baylor, PhD, Food and Drug Administration, Bethesda, Maryland; Linda Kinsinger, MD, Department of Veterans \nAffairs, Durham, North Carolina.\nLiaison Representatives: American Academy of Family Physicians, Doug Campos-Outcalt, MD, Phoenix, Arizona; American Academy of Pediatrics, \nMichael Brady, MD, Ohio State University, Columbus, Ohio, David Kimberlin, MD, Birmingham, Alabama; American Academy of Physician Assistants, \nMarie-Michèle Léger, MPH, Alexandria, Virgina; American College Health Association, James C. Turner, MD, Charlottesville, Virginia; American College \nof Obstetricians and Gynecologists, Stanley Gall, MD, Louisville, Kentucky; American College of Physicians, Gregory Poland, MD, Rochester, Minnesota;",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 19,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_20",
    "document_id": "rr6007",
    "text": "American Geriatrics Society, Kenneth Schmader, MD, Durham, North Carolina; America’s Health Insurance Plans, Mark Netoskie, MD, Houston, Texas; \nAmerican Medical Association, Litjen Tan, PhD, Chicago, Illinois; American Nurses Association, Katie Brewer, MSN, Silver Springs, Maryland; American \nOsteopathic Association, Stanley Grogg, DO, Tulsa, Oklahoma; American Pharmacists Association, Stephan L. Foster, PharmD, Memphis, Tennessee; \nAssociation of Immunization Managers, Kelly Moore, MD, Nashville, Tennessee; Association for Prevention Teaching and Research, W. Paul McKinney, \nMD, Louisville, Kentucky; Association of State and Territorial Health Officials, José Montero, MD, Concord, New Hampshire; Biotechnology Industry",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 20,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_21",
    "document_id": "rr6007",
    "text": "Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee on Immunization, Joanne Langley, MD, Halifax, \nNova Scotia, Canada; Council of State and Territorial Epidemiologists, Christine Hahn, MD, Boise, Idaho; Department of Health, United Kingdom, David \nM. Salisbury, MD, London, United Kingdom; Healthcare Infection Control Practices Advisory Committee, Alexis Elward, MD, St Louis, Missouri; Infectious \nDiseases Society of America, Samuel L. Katz, MD, Durham, North Carolina; National Association of County and City Health Officials, Matthew Zahn, MD, \nLouisville, Kentucky; National Association of Pediatric Nurse Practitioners, Patricia Stinchfield, MPH, St Paul, Minnesota; National Foundation for Infectious",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 21,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_22",
    "document_id": "rr6007",
    "text": "Diseases, William Schaffner, MD, Nashville, Tennessee; National Immunization Council and Child Health Program, Mexico, Vesta Richardson, MD, Mexico \nCity, Mexico; National Medical Association, Patricia Whitley-Williams, MD, New Brunswick, New Jersey; National Vaccine Advisory Committee, Guthrie \nBirkhead, MD, Albany, New York; Pharmaceutical Research and Manufacturers of America, Damian A. Braga, Swiftwater, Pennsylvania, Peter Paradiso, PhD, \nCollegeville, Pennsylvania; Society for Adolescent Health and Medicine, Amy Middleman, MD, Houston, Texas; Society for Healthcare Epidemiology of \nAmerica, Harry Keyserling, MD, Atlanta, Georgia.\nImmunization of Health-Care Personnel Work Group",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 22,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_23",
    "document_id": "rr6007",
    "text": "America, Harry Keyserling, MD, Atlanta, Georgia.\nImmunization of Health-Care Personnel Work Group\nAbigail Shefer, MD, National Center for Immunization and Respiratory Diseases, William Atkinson, MD, National Center for Immunization and Respiratory \nDiseases, Jane Seward, MBBS, National Center for Immunization and Respiratory Diseases, Elizabeth Bolyard, MPH, National Center for Emerging Zoonotic \nInfectious Diseases, David Kuhar, MD, National Center for Emerging Zoonotic Infectious Diseases, Suchita Lorick, MD, National Center for Immunization \nand Respiratory Diseases, Gina Mootrey, DO, National Center for Immunization and Respiratory Diseases, CDC, Atlanta; Joseph Perz, DrPH, National Center",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 23,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_24",
    "document_id": "rr6007",
    "text": "for Emerging Zoonotic Infectious Diseases, CDC, Atlanta, Georgia; Paul Cieslak, MD, Public Health Division, Oregon Health Authority, Portland, Oregon; \nKristen Ehresmann, MPH, Minnesota Department of Health, St Paul, Minnesota; Alexis Elward, MD, Washington University School of Medicine, St Louis, \nMissouri; Harry Keyserling, MD, Emory University School of Medicine, Atlanta, Georgia; ACIP liaison representatives: Jean Haulman, MD, University of \nWashington, Seattle, Washington; Mark Russi, MD, American College of Occupational and Environmental Medicine, New Haven, Connecticut; David \nWeber, MD, University of North Carolina, Chapel Hill, North Carolina.\nU.S. Government Printing Office: 2012-523-043/21089 Region IV  ISSN: 1057-5987",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 24,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_25",
    "document_id": "rr6007",
    "text": "U.S. Government Printing Office: 2012-523-043/21089 Region IV  ISSN: 1057-5987\nThe Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free \nof charge in electronic format. To receive an electronic copy each week, visit MMWR’s free subscription page at http://www.cdc.gov/mmwr/mmwrsubscribe.\nhtml. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; \ntelephone 202-512-1800.\nAddress all inquiries about the MMWR Series, including material to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 \nClifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov.",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 25,
      "total_chunks": 27
    }
  },
  {
    "chunk_id": "rr6007_chunk_26",
    "document_id": "rr6007",
    "text": "Clifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov. \nAll material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.\nUse of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.\nReferences to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations \nor their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses \nlisted in MMWR were current as of the date of publication.\nRecommendations and Reports",
    "metadata": {
      "disease_type": "immunization",
      "year": 2025,
      "guideline_name": "CDC Adult Immunization Schedule 2025",
      "section_header": "C\nR\nR\nR\nR",
      "section_type": "general",
      "source": "clinical_guideline",
      "chunk_position": 26,
      "total_chunks": 27
    }
  }
]